NCI-2022-09147

A Phase 1 Study of ASP3082 in Participants with Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies with KRAS G12D Mutation

This Phase 1 study is investigating a drug called ASP3082 in participants who have locally advanced or metastatic solid tumors that have previously been treated and carry a specific genetic mutation called KRAS G12D. The study aims to assess the safety and effectiveness of ASP3082 in this patient population. The goal is to gather important data on how well ASP3082 works against tumors with the KRAS G12D mutation and to evaluate its safety profile in participants who have already undergone prior treatment for their cancer.

Phase 1: First step in testing a new medicine in people, and tests if treatment is safe, determines the right dose, and checks for any side effects.

specific genetic mutation called KRAS: a specific type of alteration in the KRAS gene, which is part of the RAS gene family. These mutations can lead to uncontrolled cell growth and are commonly found in various cancers, impacting treatment outcomes and guiding therapeutic strategies.

locally advanced: Cancer which has grown larger into nearby tissues or organs, but hasn’t moved far from where it started

metastatic: cancer that has spread from its original location or organ to other parts of the body.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05382559

Clinical Trial Site: Columbia

To see all available clinical trials click here.